Unresectable Hepatocellular Carcinoma Therapeutics
1. Lenvima patent expiration
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; First-line treatment of patients with unresectable hepatocellular ca...
LENVIMA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(8 months from now) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(9 years from now) | |
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(9 years from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(9 years from now) | |
| US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(1 year, 6 months from now) | |
| US12226409 | EISAI INC | Treatment of hepatocellular carcinoma |
May, 2038
(12 years from now) | |
| US12083112 | EISAI INC | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
Mar, 2036
(10 years from now) | |
| US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(10 years from now) | |
|
US7612208 (Pediatric) | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Mar, 2027
(1 year, 2 months from now) | |
|
US7253286 (Pediatric) | EISAI INC | Nitrogen-containing aromatic derivatives |
Apr, 2026
(3 months from now) | |
|
US9006256 (Pediatric) | EISAI INC | Antitumor agent for thyroid cancer |
Jan, 2028
(2 years from now) | |
|
US11090386 (Pediatric) | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Aug, 2036
(10 years from now) | |
|
US11186547 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US10407393 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US12226409 (Pediatric) | EISAI INC | Treatment of hepatocellular carcinoma |
Nov, 2038
(12 years from now) | |
|
US10259791 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US12083112 (Pediatric) | EISAI INC | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
2. Nexavar patent expiration
Treatment: Treatment of carcinoma of the thyroid; Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma; Treat...
NEXAVAR's oppositions filed in EPO
NEXAVAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124630 | BAYER HLTHCARE | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(2 years ago) | |
| US8841330 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US7897623 | BAYER HLTHCARE | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US7235576 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(5 years ago) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Dosage: TABLET
How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage
NEXAVAR family patents